Colivelin trifluoroacetate salt structure
|
Common Name | Colivelin trifluoroacetate salt | ||
---|---|---|---|---|
CAS Number | 867021-83-8 | Molecular Weight | 2645.10000 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C119H206N32O35 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Colivelin trifluoroacetate saltColivelin is a neuroprotective peptide and activator of STAT3. |
Name | Colivelin |
---|---|
Synonym | More Synonyms |
Description | Colivelin is a neuroprotective peptide and activator of STAT3. |
---|---|
Related Catalog | |
Target |
STAT3 Amyloid-β |
In Vitro | Colivelin completely suppresses death induced by overexpressed FAD-causative genes and Aβ1-43 at a concentration of 100 fm, and keep its neuroprotective action at or above the levels of 1 nm[1]. Colivelin-induced neuroprotection occurs via two neuroprotective pathways: one mediated by Ca2+/calmodulin-dependent protein kinase IV, triggered by ADNF, and one mediated by signal transducer and activator of transcription 3, triggered by HN[1]. Colivelin reverses caspase3, Bax and Bcl-2 expressions in HT22 cells medaited by rmMFG-E8 in the co-cultured cells under OGD condition[4]. Colivelin (50 µg/mL, 4 hours) significantly increases the p-STAT3 protein levels in BV-2 cells[4]. Western Blot Analysis[4] Cell Line: BV-2 cells. Concentration: 50 µg/mL. Incubation Time: 4 hours. Result: Increased p-STAT3 levels. Cell Viability Assay[5] Cell Line: KYSE70 and TE8 cells. Concentration: 0.5 μM. Incubation Time: 1 hour (followed by CYT-Rx20 treatment) Result: Sgnificantly suppressed the viability in KYSE70 and TE8 cells. |
In Vivo | Colivelin (intracerebroventricular administration; 10 pmol/3 μl; 3 weeks) suppresses impairment in spatial working memory induced by repetitive intracerebroventricular injection of Aβ25-35 or Aβ1-42, in addition, it antagonizes neuronal loss in the CA1 region of hippocampus induced by hippocampal injection of Aβ1-42[1]. Colivelin (intraperitoneal administration; 1.4, 7, or 35 nM/0.21 mL; on the Y-maze testday) suppresses memory impairment caused by 3-quinuclidinyl benzilateand restricts functional memory deficit[1]. Colivelin (intraperitoneal injection; 1 mg/kg; 14 days) results in improved motor and cognitive function with time by performance of mNSS, rotarod, and corner turning test.It also reduces lesion volume and improves neurological deficits after MCAO[3]. Animal Model: CD-1 mice[1] Dosage: 10 pmol/3 μl Administration: Intracerebroventricular administration Result: Completely suppressed Aβ 25-35-mediated impairment in spatial working memory and increased the number of immunoreactive neurons. Animal Model: C57 mice[1] Dosage: 1.4, 7, or 35 nM/0.21mL Administration: Intraperitoneal administration Result: Protected against cholinotoxin-induced amnesia in mice. Animal Model: Male C57BL/6 mice[3] Dosage: 1 mg/kg Administration: Intraperitoneal administration Result: Protected against ischemic brain injury, and improves neurological outcomes |
References |
Molecular Formula | C119H206N32O35 |
---|---|
Molecular Weight | 2645.10000 |
Exact Mass | 2643.53000 |
PSA | 1043.77000 |
LogP | 2.51360 |
H-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro-OH |
Remacemide hydrochloride |